US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

In the paper in "Journal of Colloid And Interface Science ", the Attana quartz crystal microbalance (QCM) is applied to study the electrical response of two ionic liquids. Controlled by an applied electric field, the structure and interaction of ionic liquids on the surface, can be monitored and optimized. This is of high importance for the development of e.g. environment friendly lubricants. This is the third paper by the team of Prof Rutland that demonstrates how Attana technology can be applied to monitor interaction

Attana’s presentation from Småbolagsdagarna is now available on YouTube

On June 14, Attana attended Aktiespararna’s Småbolagsdagarna where CEO, Teodor Aastrup, gave a 20-minute-long presentation followed by a 10-minute-long Q&A.The presentation was held in Swedish and primarily focused on Attana’s history and milestones, followed by Attana’s ongoing work within both its business areas – Life Science and Diagnostics. The presentation concluded with Attana long-term, 2030 plan. The presentation can be accessed by following this link: Attana – Småbolagsdagarna 2022 

Attana’s presentation from Biotech Showcase 2022 is now available on Attana’s website

January 10–19, Attana is participating in one of the largest biotech conferences in the world – Biotech Showcase. Attana is attending the digital conference and have published a presentation as well as participated in digital one-to-one meetings.The presentation was held in English and primarily focused on Attana’s ongoing diagnostic work and its two business units – Life Science and Diagnostics. The presentation can be accessed on Attana’s website by following this link: Attana – Biotech Showcase 2022 

New PhD thesis uses QCM sensor from Attana to investigate protein interactions on inflammatory cells

In a recent PhD thesis published from Uppsala University Attana technology was used to study blood protein binding to inflammatory cells.Attana technology has been applied by Dr. Tor Persson Skare in Professor Lena Claesson-Welsh’s group at Uppsala University in their study of Histidine-rich protein (HRG) and Stanniocalcin 2 (STC2) interactions and their effects on inflammatory cells. Both HRG and STC2 are found in blood and have been shown to have an impact on inflammatory processes. In the PhD thesis, a manuscript with the title “Histidine-rich glycoprotein and stanniocalcin-2 high

Update following Attana’s participation at the Drug Discovery V-Forum

On April 21, Attana participated in the conference Drug Discovery V-Forum to present the company and listen in to presentations from other companies within the Life Science industry.This marked yet another conference where Attana had the opportunity to communicate its products and services to potential customers and partners. The company also presented preliminary results from the ongoing work with Attana Diagnostics and the development of a SARS-CoV-2 immunoassay. Attana’s recorded presentation can be found here .

Attana implements organizational changes and accelerates the development of Attana Diagnostics with COVID-19 tests leading the way

Attana can today announce that the company has strengthened its collaboration with the Linnaeus University to accelerate the development of unique antibody tests for COVID-19. Furthermore, the company moves forward with the regulatory efforts for AVA™ and implements a number of organizational changes aimed to establish an expert team leading the diagnostics initiative independent of Attana's ongoing operations.Strengthened collaboration with the Linnaeus UniversityThe Linnaeus University in Kalmar installed its first Attana instrument as early as 2003, and in 2019 the university was

Release of initial Attana Virus Analytics-AVA testing protocols

Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers.In close collaboration with Linnaeus University Attana application specialists have been performing studies on serum samples to detect and characterize COVID-19 antibodies using the Attana Cell™ 200 system. By optimizing the testing procedures, two protocols have now successfully been established and preparations are being made for the scientific publication of corresponding technical notes. The AVA Antibody-Testing protocols are comprised of

Attana launches the Attana Cell 250

Attana has today launched the Attana Cell 250 instrument which features a new and fully integrated autosampler, delivering vastly improved sample handling and instrument operation.Since 2019, Attana has been working closely with ModuVision Technologies BV (Vlissingen, The Netherlands) to integrate their flagship product, the PRIMARIZ robotic autosampler, into the Attana system. The Attana Cell 250 is the first result of this cooperation. “We are proud to welcome Attana to our ever-growing customer base and with this, enter into new application fields,” comments Jan Willem Mol, CEO of

Attana introduces Attana Virus Analytics to support global COVID-19 testing efforts

Since the advent of the COVID-19 outbreak Attana has been engaged by select customers to assist in their development of novel vaccine candidates and potential virus treatments. In these efforts, Attana instruments have routinely been used to analyze serum samples in real time, generating in-depth data of both virus and antibody presence. Given the strong global demand for COVID-19 testing and in particular, accurate antibody testing, Attana has introduced Attana Virus Analytics (AVA) and commenced discussions with various potential customers including international government entities

Potential COVID-19 vaccine passes important milestone

Since March, Attana has been assisting the team of Prof Ali Salanti at the University of Copenhagen in their development of a COVID-19 vaccine together with the Prevent-nCov consortium. Their vaccine is based on the Capsid Virus-Like Particle (cVLP) technology where coronavirus antigens are attached to the cVLP allowing the body’s immune system to respond to the antigens and produce antibodies.During the past two months the vaccine has been tested in mice which produced large amounts of antibodies able to neutralize SARS-CoV-2 virus and the response was several hundred times stronger than

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe